



Patient-Focused Drug Development Public Meeting and Scientific workshop on Female Sexual Dysfunction

FDA is conducting a Patient-Focused Drug Development public meeting and scientific workshop on Female Sexual Dysfunction (FSD) on October 27 and October 28.

Day 1 – October 27th Patient-Focused Drug Development Public Meeting

FDA is interested in obtaining patient input on:

1. The impact of the most common form of FSD, female sexual interest/arousal disorder (FSIAD) on daily life
2. Patients' views on currently available therapies to treat the condition

Day 2 – October 28th Scientific Workshop

The scientific workshop will include discussion on scientific challenges related to:

1. Diagnosis of the condition for clinical trials and in clinical practice
2. Ensuring valid patient-reported outcome measures for the key efficacy endpoints used in clinical trials

Date(s) and Time(s)

October 27, 2014 (12:00 p.m. to 5:00 p.m.)

October 28, 2014 (8:00 a.m. to 5:00 p.m.)

Location

FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B and C
Silver Spring, MD 20993

[\(Information about arrival to FDA's White Oak campus\)](#)

Remote access will be available via live webcast for those unable to attend in person.

Registration

To register for this meeting, visit <http://patient-focused-female-sexual-dysfunction.eventbrite.com>.

Please note that registration for in-person attendance and the webcast closes on **October 20, 2014**.